The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

6 questions to CEO Ian Crosbie, May 2023

alfapump DSR® – combines Sequana Medical’s breakthrough DSR therapy with its alfapump®

DSR® – potential new treatment for diuretic-resistant fluid overload due to heart failure

Heart failure and diuretic-resistant fluid overload

alfapump® – new ascites treatment for more quality of life

Recovered quality of life with the alfapump® system

Ascites and NASH related Cirrhosis

The alfapump® for the management of fluid overload

POSEIDON study interim results – November 2020

RED DESERT study interim results – October 2020

alfapump DSR® therapy in heart failure